RxDoctor Payments Data

Katina Huff, PA

Physician Assistant · Sparta, TNNPI 1093826463

Payments from drug & device makers

$605in general payments, 2019–2025

Across 34 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$259
  • Merck$71
  • Pfizer$58
  • Amgen$52
  • Sanofi-aventis U.S. LLC$46
  • Lilly USA, LLC$43
  • plus $76 from 4 others

What the payments were for

  • Food & beverage$605100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie14$259
Merck4$71
Pfizer3$58
Amgen4$52
Sanofi-aventis U.S. LLC2$46
Lilly USA, LLC3$43
PBG Puerto Rico LLC1$24
Novo Nordisk1$21
AstraZeneca1$17
Phathom Pharmaceuticals, Inc.1$15

How this compares

$605 in reported general payments places this provider in the 60th percentile of 2,404 physician assistant providers in Tennessee.

See all physician assistant providers in Tennessee

Medicare billing

Part B allowed, 2024
$87,126
Medicare patients
144
Services billed
1,839

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$49,171
EliquisApixaban47$43,215
FarxigaDapagliflozin Propanediol45$34,667
MounjaroTirzepatide23$23,041
Tresiba Flextouch U-200Insulin Degludec16$10,794
ShingrixVaricella-Zoster Ge/As01b/Pf37$7,863
SymbicortBudesonide/Formoterol Fumarate17$4,484
Albuterol Sulfate HfaAlbuterol Sulfate95$4,019
Atorvastatin Calcium306$3,943
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$3,655
Omeprazole178$3,641
Rosuvastatin Calcium182$2,856
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,722
Levemir FlexpenInsulin Detemir19$2,556
Clonidine13$2,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$21$49,17134 claims
PfizerEliquis$58$43,21547 claims
AstraZenecaFarxiga, Symbicort$17$39,15262 claims
Lilly USA, LLCMounjaro$43$23,04123 claims
Sanofi-aventis U.S. LLCLantus$46$1,22211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,404 physician assistant providers in Tennessee.

Other physician assistant in Sparta

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →